MedPath

Coenzyme Q10

Generic Name
Coenzyme Q10
Drug Type
Small Molecule
Chemical Formula
C59H90O4
CAS Number
303-98-0
Unique Ingredient Identifier
EJ27X76M46
Background

Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand. Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.

Indication

The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies. It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.

Associated Conditions
Migraine

The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer

Phase 1
Recruiting
Conditions
Colorectal Cancer
Interventions
First Posted Date
2025-03-04
Last Posted Date
2025-03-04
Lead Sponsor
toqa saad mohammed mohammed
Target Recruit Count
22
Registration Number
NCT06856447
Locations
🇪🇬

Ain-Shams University Hospital, Cairo, Egypt

The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery

Phase 4
Recruiting
Conditions
Postoperative Pain
Interventions
Other: Placebo
First Posted Date
2024-12-20
Last Posted Date
2025-02-26
Lead Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Target Recruit Count
264
Registration Number
NCT06743802
Locations
🇨🇳

Guangyou Duan, Chongqing, Chongqing, China

Effect Supplementation of COenzyme Q10 in Acute STEMI Underwent PPCI

Not Applicable
Completed
Conditions
ST Segment Elevation Myocardial Infarction (STEMI)
Coenzyme Q10
Interventions
Drug: Placebo
First Posted Date
2024-10-28
Last Posted Date
2024-10-28
Lead Sponsor
Universitas Diponegoro
Target Recruit Count
46
Registration Number
NCT06661018
Locations
🇮🇩

Dr. Kariadi Central General Hospital, Semarang, Central Java, Indonesia

Prevent Cardiac Surgery Associated AKI Trial

Phase 2
Recruiting
Conditions
Renal Failure
Coronary Artery Disease
Surgery
Surgery-Complications
Interventions
First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
George Washington University
Target Recruit Count
242
Registration Number
NCT06620523
Locations
🇺🇸

George Washington University Hospital, Washington, District of Columbia, United States

Ubiquinone vs. Ubiquinol Supplementation

First Posted Date
2024-08-15
Last Posted Date
2025-04-10
Lead Sponsor
Trio Fertility
Target Recruit Count
90
Registration Number
NCT06555575
Locations
🇨🇦

Trio Fertility, Toronto, Ontario, Canada

Reducing Fatigue With CoQ10 Supplementation in Patients With Crohn's Disease Study

Early Phase 1
Conditions
Crohn Disease
Healthy
Interventions
First Posted Date
2024-05-17
Last Posted Date
2024-08-16
Lead Sponsor
University of Pennsylvania
Target Recruit Count
60
Registration Number
NCT06419335
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR)

Early Phase 1
Not yet recruiting
Conditions
Poor Ovarian Response
Interventions
Drug: Jiajian Guishen granules
First Posted Date
2023-10-18
Last Posted Date
2024-05-02
Lead Sponsor
Shi Yun
Target Recruit Count
76
Registration Number
NCT06089395
Locations
🇨🇳

Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, Beijing, China

🇨🇳

Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China

Coenzyme Q10 and Dentoalveolar Cyst

Phase 2
Active, not recruiting
Conditions
Cyst, Jaw
Interventions
Drug: control group
First Posted Date
2023-05-24
Last Posted Date
2025-03-03
Lead Sponsor
Fayoum University
Target Recruit Count
20
Registration Number
NCT05873673
Locations
🇪🇬

Fayoum University, Fayoum, Egypt

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

Early Phase 1
Withdrawn
Conditions
Sarcopenia
Interventions
Other: Placebo
First Posted Date
2021-08-10
Last Posted Date
2023-07-24
Lead Sponsor
AdventHealth Translational Research Institute
Registration Number
NCT04999488
Locations
🇺🇸

AdventHealth Translational Research Institute, Orlando, Florida, United States

Coenzyme Q10 as Treatment for Long Term COVID-19

Phase 2
Completed
Conditions
Covid19
Long Term Covid19
Interventions
Drug: Placebo
First Posted Date
2021-07-13
Last Posted Date
2022-05-06
Lead Sponsor
Aarhus University Hospital
Target Recruit Count
121
Registration Number
NCT04960215
Locations
🇩🇰

Department of Infectious Diseases, Aarhus, Aarhus N, Denmark

© Copyright 2025. All Rights Reserved by MedPath